^
Association details:
| Biomarker: | TGFB1 elevation |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) + galunisertib (LY2157299) (Phosphotransferase inhibitor, TGF-β1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase 2 Study of Galunisertib (TGF-ß1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Published date:
07/01/2019
Excerpt:
Patients with baseline AFP ≥ 400 ng/mL or patients with baseline TGF-β1 ≥ baseline median (1956 pg/mL) demonstrated trends toward longer TTP.
DOI:
10.14309/ctg.0000000000000056
Trial ID:
